The stock of NeoGenomics, Inc. (NASDAQ:NEO) is a huge mover today! About 98,380 shares traded hands. NeoGenomics, Inc. (NASDAQ:NEO) has risen 8.67% since March 7, 2016 and is uptrending. It has outperformed by 1.08% the S&P500.
The move comes after 7 months positive chart setup for the $638.62 million company. It was reported on Oct, 10 by Barchart.com. We have $10.74 PT which if reached, will make NASDAQ:NEO worth $191.59 million more.
Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on November, 3. NEO’s profit will be $773,148 for 206.50 P/E if the $0.01 EPS becomes a reality. After $0.02 actual earnings per share reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.
NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage
Out of 7 analysts covering NeoGenomics (NASDAQ:NEO), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. NeoGenomics has been the topic of 9 analyst reports since September 3, 2015 according to StockzIntelligence Inc. On Friday, March 11 the stock rating was initiated by Benchmark with “Buy”. Roth Capital maintained NeoGenomics, Inc. (NASDAQ:NEO) on Thursday, September 3 with “Buy” rating. The stock has “Overweight” rating given by First Analysis on Tuesday, October 4. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by TH Capital on Monday, October 26. As per Sunday, September 6, the company rating was maintained by William Blair. Roth Capital reinitiated the stock with “Buy” rating in Wednesday, May 11 report. The firm has “Neutral” rating by BTIG Research given on Wednesday, July 27.
According to Zacks Investment Research, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.”
Insitutional Activity: The institutional sentiment increased to 2 in 2016 Q2. Its up 0.78, from 1.22 in 2016Q1. The ratio improved, as 5 funds sold all NeoGenomics, Inc. shares owned while 34 reduced positions. 36 funds bought stakes while 42 increased positions. They now own 57.99 million shares or 3.94% more from 55.79 million shares in 2016Q1.
Artisan Prtnrs Partnership last reported 0.05% of its portfolio in the stock. Us Savings Bank De holds 0% or 11,635 shares in its portfolio. Northern Corporation holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 881,140 shares. California Employees Retirement Sys holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 87,100 shares. Emerald Advisers Pa accumulated 300,160 shares or 0.12% of the stock. Legacy Capital holds 0.3% or 60,000 shares in its portfolio. Blackrock Gp Limited reported 11,522 shares or 0% of all its holdings. Savings Bank Of America Corporation De accumulated 0% or 9,789 shares. Howland Cap Mgmt Limited Liability accumulated 13,000 shares or 0.01% of the stock. Cambridge Inv Advisors accumulated 15,300 shares or 0% of the stock. Teacher Retirement Systems Of Texas last reported 8,179 shares in the company. Blackrock Fund Advsr accumulated 0% or 1.38M shares. Tower Limited Liability (Trc) last reported 0% of its portfolio in the stock. The Washington-based Parametric Port Associates Limited Liability has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Coe Mngmt Lc has 66,545 shares for 0% of their US portfolio.
Insider Transactions: Since April 20, 2016, the stock had 0 buys, and 9 selling transactions for $11.28 million net activity. The insider ROSS STEVEN A sold $912,375. 481,387 shares with value of $4.20M were sold by VAN OORT DOUGLAS M on Wednesday, May 25. JONES STEVEN C sold $1.46M worth of stock or 177,745 shares. ALBITAR MAHER also sold $863,460 worth of NeoGenomics, Inc. (NASDAQ:NEO) shares.
More notable recent NeoGenomics, Inc. (NASDAQ:NEO) news were published by: Fool.com which released: “Why Neogenomics Inc is Soaring Higher Today” on October 21, 2015, also Prnewswire.com with their article: “NeoGenomics Completes Acquisition of Clarient, Inc.” published on December 30, 2015, Quotes.Wsj.com published: “NeoGenomics Inc. NEO (US: Nasdaq)” on May 30, 2011. More interesting news about NeoGenomics, Inc. (NASDAQ:NEO) were released by: Prnewswire.com and their article: “NeoGenomics signs Definitive Agreement to acquire Clarient, Inc.” published on October 21, 2015 as well as Marketwatch.com‘s news article titled: “NeoGenomics started at buy with $8 stock price target at Benchmark” with publication date: November 20, 2012.
NEO Company Profile
NeoGenomics, Inc., incorporated on October 28, 1998, is an operator of a network of cancer-focused genetic testing laboratories. The Firm operates in Laboratory Testing Segment. The Company’s Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Firm has laboratory locations in Ft. Myers and Tampa, Florida; Fresno, Irvine, and West Sacramento, California, and Nashville, Tennessee. The Firm offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues; molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level; Pathology consultation- services provided for clients in which the Company’s pathologists review surgical samples on a consultative basis, and Pharma Services and Clinical Trials-Services supporting pharmaceutical firms in their drug development programs by supporting various clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.